Algebra Ventures

Algebra Ventures is Egypt’s premier venture capital firm, managing over $150M across two funds with Fund I closed in 2016 at $54M and Fund II closed in 2022 at approximately $90M to $100M from a diverse LP base including IFC, DFIs, government institutions, corporate investors, and family offices. The fund writes Seed and Series A checks in the $500k to $5M range and has been actively backing AI healthtech, including DeepEcho, the Moroccan FDA-cleared fetal ultrasound AI platform that has raised funding from Algebra alongside Plug and Play, UM6P Ventures, and Al Mada Ventures. The right founder is an Egyptian, North African, or pan-African technical or commercial operator with credible product-market fit, ambition to build a category-defining business, and a plan that respects African operating realities. Healthcare relevance includes diagnostic AI, clinical AI, digital health platforms, telemedicine, scalable health infrastructure, and B2B SaaS targeting African providers and payers. Founders pursuing biotech assets with multi-year R&D timelines, capital-intensive devices, or pure consumer brands should look at specialist funds. Geographic advantage is significant: Algebra is the most institutional Egyptian early-and-growth-stage VC, with deep relationships across Egyptian regulators, corporates, and family offices, plus pan-African reach and global LP connectivity that opens doors with US and European Series A and B leads. Best entry is a warm intro from a portfolio founder or a regional co-investor such as Endure Capital, Disruptech, or Foundation Ventures. Cold inbound is read but conversion is lower. Lead the pitch with real revenue or strong demand-side signals, a credible international or pan-African expansion plan, and technical or scientific depth. AI healthcare founders should describe FDA or CE strategy where relevant, training data provenance, model evaluation rigor, and how patient consent and data residency are handled across African jurisdictions. Caveats: Egyptian and African Series B capital remains structurally scarce for healthcare specifically, so founders should plan the bridge from Series A to international growth-stage capital early. Egyptian pound volatility shapes operating budgets, and savvy founders structure rounds with FX hedging and dollar-denominated holding structures. Ask Algebra about reserves, prorata behavior, and which Series B and C leads have followed it into healthcare portfolio companies. Reference checks with current portfolio CEOs on operating support, regulator navigation, and US and European introductions are worth the time. Used appropriately, Algebra is the most credible Egyptian institutional partner for healthcare AI founders building from Egypt or broader Africa toward international scale.